华邦健康(002004) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 2,915,489,646.11, a decrease of 2.02% compared to CNY 2,975,546,798.68 in the same period last year[4] - Net profit attributable to shareholders was CNY 155,559,826.48, down 12.18% from CNY 177,137,767.78 year-on-year[4] - The net profit for Q1 2024 was CNY 214,428,922.38, a decrease of 27.3% compared to CNY 294,842,240.23 in Q1 2023[16] - The company reported a net profit margin of approximately 9.1% for Q1 2024, down from 10.0% in the previous year[15] - The total comprehensive income for Q1 2024 was CNY 206,638,623.59, compared to CNY 288,514,789.42 in Q1 2023, indicating a decrease of 28.4%[17] Cash Flow - The net cash flow from operating activities increased significantly to CNY 111,518,296.72, a 970.31% improvement from a negative cash flow of CNY 12,813,669.92 in the previous year[4] - The company reported a net cash flow from operating activities of CNY 111,518,296.72, a significant improvement from a negative cash flow of CNY -12,813,669.92 in Q1 2023[18] - The net cash outflow from investing activities was CNY -573,043,653.12, worsening from CNY -47,494,377.09 in the previous year[18] - The net cash flow from financing activities surged to CNY 731,469,429.37, a 10,407.96% increase compared to a negative cash flow of CNY 7,096,160.62 in the previous year[7] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 31,479,044,092.04, reflecting a 2.45% increase from CNY 30,727,396,560.35 at the end of the previous year[4] - Total assets as of March 31, 2024, were CNY 31,479,044,092.04, compared to CNY 30,727,396,560.35 at the beginning of the year, indicating a growth of 2.4%[14] - Total liabilities increased to CNY 14,701,068,409.09 from CNY 14,142,663,368.26, marking a rise of 3.9%[14] - The total liabilities decreased to CNY 1,463,122,026.94 in financing activities, down from CNY 1,695,183,231.01 in Q1 2023[18] Shareholder Information - The company reported a total of 81,245 common shareholders at the end of the reporting period[9] - The largest shareholder, Tibet Huibang Technology Co., Ltd., holds 18.71% of the shares, totaling 370,449,804 shares[9] Operating Costs and Income - Total operating revenue for Q1 2024 was CNY 2,915,489,646.11, a decrease of 2.0% compared to CNY 2,975,546,798.68 in the same period last year[15] - Total operating costs for Q1 2024 were CNY 2,650,059,150.01, an increase of 0.4% from CNY 2,639,200,698.31 in the previous year[15] - The company experienced a 44.22% decrease in other income, which amounted to CNY 12,737,122.18 compared to CNY 22,833,936.89 in the previous year[7] - Investment income fell by 35.42% to CNY 6,458,725.60 from CNY 10,000,471.18 year-on-year[7] Equity and Earnings - The company's equity attributable to shareholders rose to CNY 10,242,389,368.08 from CNY 10,105,176,600.57, an increase of 1.4%[14] - The weighted average return on equity decreased to 1.52%, down from 1.72% in the same period last year[4] - The basic and diluted earnings per share for Q1 2024 were both CNY 0.0786, down from CNY 0.0895 in Q1 2023, reflecting a decline of 12.3%[17] Inventory and Receivables - Accounts receivable increased to CNY 1,947,179,760.24 from CNY 1,502,404,277.71, reflecting a growth of 29.7%[12] - Inventory decreased to CNY 2,507,214,008.25 from CNY 2,674,605,594.89, a decline of 6.3%[13] Research and Development - Research and development expenses were CNY 94,529,223.40, a decrease of 7% from CNY 101,564,101.36 in the same period last year[16]